Randomized trial: Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19

Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial – Clinical Infectious Diseases

Related Study: Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report – New England Journal of Medicine

Commentary on Twitter

Metcovid Double Blind PH. 2
RCT 🇧🇷~ 400 pts #CID
Methylprednisolon 0.5mg/kg twice daily x5d #COVID19 Hospitalized pts #COVID19 did not reduce 28d mortality V placebo
Is it Right Drug, Dose, Duration
High dose vs RECOVERY
DEX less mineralocorticoid
5 v 10 https://t.co/EBIRWYouSQ pic.twitter.com/OzGJkqjkrJ

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) August 13, 2020